Torii Pharmaceutical Co (TSE:4551) Net Income From Continuing Operations : 円5,288 Mil (TTM As of Mar. 2024)

View and export this data going back to 1993. Start your Free Trial

What is Torii Pharmaceutical Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Torii Pharmaceutical Co's net income from continuing operations for the three months ended in Mar. 2024 was 円879 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was 円5,288 Mil.

Torii Pharmaceutical Co Net Income From Continuing Operations Historical Data

The historical data trend for Torii Pharmaceutical Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Torii Pharmaceutical Co Net Income From Continuing Operations Chart

Torii Pharmaceutical Co Annual Data

Trend

Mar14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

37,700.00

4,225.00

4,767.00

5,722.00

5,593.00

Torii Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income From Continuing Operations	Get a 7-Day Free Trial															-289.00	1,376.00	1,281.00	1,752.00	879.00

Torii Pharmaceutical Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円5,288 Mil.

Torii Pharmaceutical Co (TSE:4551) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Torii Pharmaceutical Co Ltd (TSE:4551) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

Torii Nihonbashi Buildingg, 4-1, Nihonbashi-Honcho, 3-chome, Chuo-ku, Tokyo, JPN, 103-8439

Website

http://www.torii.co.jp

Torii Pharmaceutical Co Ltd is a major drug manufacturing company. The company utilizes strategic partnerships with other pharmaceutical companies in order to combine research and marketing functions. Torii's key therapeutic areas include renal diseases, hemodialysis, HIV, skin diseases, and allergens. The vast majority of the company's net mainstay product sales are derived from the renal diseases and hemodialysis operations, followed by HIV. Torii's places its strategic focus on prompt market penetration and expansion of new products as well as maximizing values of mainstay products in each priority area.

Torii Pharmaceutical Co (TSE:4551) Headlines

No Headlines